

SEP-11-2007 TUE 04:30 PM astra zeneca r&d boston

FAX NO. 17818394121

P. 01

10/551259



Fax

To	Fax number
Alvarado M. Winston	571 270 9878
PCT Office of PCT Operations	
United States Patent and TradeMark Office	
From	Fax number
John X. Haberman/Global Intellectual Property, Patents	+1 781 839 4736
Copies	Date
	September 11, 2007
Subject	Total pages
US Application No.: 10/551,259	8
	Reference
	Our Ref 100995-1P US

Dear Sir

Please find attached the Preliminary Amendment for US Application No.: 10/551,259, as requested from your telephone conversation of September 10, 2007.

Yours faithfully

A handwritten signature in black ink, appearing to read "J. X. Haberman".

John X. Haberman
Patent Attorney

Encs

This message, including any attachments, is confidential, intended only for the recipient, and may be a confidential attorney client communication or may otherwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer. Thank you.

AstraZeneca
Global Intellectual Property
35 Gatehouse Drive
Waltham, MA 02451-1215

Tel: +01 781 839-4000
Fax: +01 781 839-4121
www.astrazeneca-us.com

AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, Massachusetts 02451-1215
USA

PTO/SB/21 (09-04)

Approved for use through 07/31/2005. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

7

Application Number	10/551,259
Filing Date	09/27/2005
First Named Inventor	Beth Andrews
Art Unit	1655
Examiner Name	Not yet known
Attorney Docket Number	100995-1P US


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AstraZeneca		
Signature			
Printed name	John X. Haberman		
Date	09/11/07	Reg. No.	55,236

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature 

Typed or printed name

Audrey Williams

Date

09/11/2007

This collection of information is required by 37 CFR 1.6. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/551,259	Applicant: Andrews et al
Filing Date: 09/27/2005	Attorney Docket No.: 100995-1P US
Examiner: Not yet known	Group Art Unit: 1655
Customer No.: 44992	Confirmation No.: 3367
Title: TOPOISOMERASE MODULATOR ASSAYS	

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office on
September 11, 2007

A handwritten signature of Audrey Williams.

Audrey Williams

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Prior to calculation of the claim fees and examination of the application on its merits, please
amend it as follows:

Amendments to the claims begin on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.